Article

Patient radiation dose and lifetime attributable risk of cancer due to ionizing radiation in cardiovascular interventional radiological procedures

¹ Department of Medical Imaging and Radiation Sciences, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
² Department of Anatomical Science, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
³ Department of Biomedical Engineering and Medical Physics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
⁴ Department of Cardiac Angiography, Abu Ali Sina Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

^* Corresponding author: mh_jamshidi@yahoo.com

Received: 20 October 2021
Accepted: 24 March 2022

Abstract

The aim of this study is to calculate the patient radiation dose and Lifetime Attributable Risk (LAR) in Cardiovascular Interventional Radiological (CVIR) procedures. The patient population included 327 patients who underwent Coronary Angiography (CA) and Percutaneous Coronary Interventions (PCI). Exposure data were reported for every examination such as Kerma-Area Product (KAP), fluoroscopy time and number of exposures. Organ dose and effective dose were assessed by PCXMC software. LAR values were determined according to BEIR VII report. The mean effective dose per examination in CA is 12.6 mSv for males and 10.25 mSv for females. In PCI, the mean effective dose is 18.06 mSv for males and 22.73 mSv for females. Organs with highest dose are thymus, heart, breast, and lung. The mean of LAR value in CA is 62 and 60 for males and females, respectively. In PCI, the mean of LAR value is 89 and 132 for males and females, respectively. Also, the KAP to effective dose conversion factors (CF_KAP-ED) were calculated. CF_KAP-ED for CA is 0.249 in males and 0.228 in females, and for PCI is 0.2446 and 0.2316 for males and females, respectively. This study will help better understand the concept of ionizing radiation dose in the CVIR procedures and how the individual patient’s effective dose and LAR can evaluate the cancer risk.